SCHEMBL29133751

SCHEMBL29133751

Cc1ncc(-c2ccc3ncnc(NCCc4ccccc4)c3c2)cc1NS(C)(=O)=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.68
PIK3CA P42336 6/20 0.60
PRKDC P78527 1/20 0.55
CYP1A2 P05177 7/20 0.53
CYP3A4 P08684 7/20 0.53
USP2 O75604 6/20 0.53
LMNA P02545 4/20 0.53
CYP2D6 P10635 4/20 0.53
MAPK1 P28482 4/20 0.53
CYP2C19 P33261 3/20 0.53
TSHR P16473 3/20 0.53
HIF1A Q16665 3/20 0.53
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 2/20 0.53
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP2C9 P11712 2/20 0.53
RAF1 P04049 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27170398 0.90 EGFR (0.84) EGFRPIK3CAPRKDCCYP1A2CYP3A4
SCHEMBL29133777 0.88 PIK3CA (0.75) EGFRPIK3CACYP1A2CYP3A4LMNA
SCHEMBL29133765 0.85 EGFR (0.54) EGFRPIK3CAPRKDCCYP1A2CYP3A4
SCHEMBL29133708 0.85 EGFR (0.82) EGFRPIK3CACYP1A2CYP3A4USP2
SCHEMBL29133712 0.83 MAPK1 (0.55) EGFRPIK3CACYP1A2CYP3A4USP2
Formamide SCHEMBL29133744 0.82 MAPK1 (0.51) EGFRPIK3CACYP1A2CYP3A4USP2
SCHEMBL24576531 0.81 EGFR (1.00) EGFRPIK3CAPRKDCCYP1A2CYP3A4
SCHEMBL24576509 0.81 EGFR (0.81) EGFRPIK3CAPRKDCCYP1A2CYP3A4
SCHEMBL27170399 0.81 EGFR (0.70) EGFRPIK3CAPRKDCCYP1A2CYP3A4
SCHEMBL29133726 0.80 MAPK1 (0.61) EGFRCYP1A2CYP3A4USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117295716-A Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors 麦克尼斯迪克治疗有限公司 2023-12-26 CN disclosed